Please login to the form below

Not currently logged in
Email:
Password:

Former Quintiles president Jeff Thomis to chair Idis

Will oversee company’s activities to develop managed access programmes for medicines

Idis Jeff ThomisIdis has appointed Jeff Thomis as chairman to oversee the company's activities in creating managed access programmes for medicines.

The appointment marks a change of direction for Thomis, who has spent a large part of his career in the management of clinical trials.

This includes 11 years at clinical research organisation (CRO) Quintiles, which he joined in 1998 as president clinical development Europe before being appointed as president of global clinical development services in 2006.

In his new role, Thomis will work with the board of Idis and its leadership team to develop programmes for pharma and biotech companies to provide unapproved medicines to patients with unmet medical needs.

“As specialists in the field, Idis is strongly placed to deliver highly effective solutions to our customers who include pharmaceutical and biotech companies, healthcare professionals and patients,” said Thomis.

Prior to his time at Quintiles, Thomis was director of infectious diseases at Bristol-Myers Squibb.

6th September 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics